Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year Low - Here's Why

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock price reached a new 52-week low on Wednesday . The company traded as low as $18.62 and last traded at $18.66, with a volume of 1793889 shares. The stock had previously closed at $19.58.

Analyst Ratings Changes

Several equities research analysts have weighed in on GMAB shares. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Truist Financial decreased their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $41.33.

Genmab A/S Stock Performance

The business's 50 day moving average price is $20.67 and its 200-day moving average price is $21.57. The firm has a market capitalization of $12.17 billion, a PE ratio of 10.57, a P/E/G ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its holdings in Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock valued at $636,000 after purchasing an additional 12,654 shares during the period. FMR LLC boosted its stake in shares of Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock valued at $6,782,000 after buying an additional 33,076 shares during the period. Verition Fund Management LLC acquired a new position in shares of Genmab A/S during the third quarter worth about $709,000. HighTower Advisors LLC purchased a new stake in shares of Genmab A/S during the third quarter worth approximately $273,000. Finally, Quantinno Capital Management LP raised its holdings in Genmab A/S by 56.8% in the third quarter. Quantinno Capital Management LP now owns 24,207 shares of the company's stock valued at $590,000 after acquiring an additional 8,766 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.